NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









OncoNano Medicine

OncoNano Medicine

Private
Southlake, TexasHealthcare & Life Scienceshttps://www.onconano.com/

Last Round

Series B

Extension

Jun 2, 2025

Est. Valuation

$60M

Total Funding Raised

$216.27M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

OncoNano Medicine is a biotechnology company that develops pH-activated compounds designed to detect and treat diseased tissue, with a focus on enhancing cancer treatment during surgery and post-operative evaluation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical Imaging

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

drug delivery platformpH-sensitive micellesoncology therapeuticsSTING agonisttargeted cancer therapydrug delivery techtumor microenvironmentbiopharma licensingclinical-stage biotechnanomedicinecancer drug deliveryimaging agentsbiotech partnershipdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

OncoNano Medicine Comps

Public and private peers based on sector, stage, and business model.

OncoNano Medicine comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

OncoNano Medicine Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionJun 2, 2025
Series BOct 25, 2021
Series BJun 17, 2021
GrantAug 20, 2020
GrantAug 27, 2019
Series A
Jul 9, 2019

Key People

Founding team and executive leadership

Kartik Krishnan

Chief Executive Officer

Executive Team

Matthew Head

CFO

Executive Team

OncoNano Medicine Investors

Notable investors and investment history

OncoNano Medicine investors
InvestorRounds
Advantech CapitalSeries B
Salem PartnersSeries B Extension, Series A
Cancer Prevention and Research Institute of TexasGrant, Series B
Cancer Prevention and Research Institute of Texas (CPRIT)Grant, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Presenting preclinical data at the AACR Annual Meeting 2026.

  • Jan 6, 2026

    Partnering with Gilead Sciences to evaluate encapsulation technology.

OncoNano Medicine Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

OncoNano Medicine Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about OncoNano Medicine's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouthlake, Texas
Employee Range22
Year Founded2014
Last FundingJun 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.